(Q46405747)

21 December 2017

title

Major inter-laboratory variations in PSA testing practices: results from national surveys in Ireland in 2006 and 2007. (English)

1 reference

21 December 2017

author name string

F J Drummond

series ordinal

1

1 reference

21 December 2017

L Sharp

series ordinal

2

1 reference

21 December 2017

H Comber

series ordinal

3

1 reference

21 December 2017

publication date

8 October 2008

1 reference

21 December 2017

Irish Journal of Medical Science

published in

1 reference

21 December 2017

volume

177

1 reference

21 December 2017

issue

4

1 reference

21 December 2017

page(s)

317-323

1 reference

21 December 2017

Translating Science to Practice

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11845-008-0216-1

Screening for prostate cancer

21 January 2018

1 reference

12 December 2020

How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be?

1 reference

12 December 2020

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

1 reference

12 December 2020

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

12 December 2020

Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom

1 reference

12 December 2020

Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma.

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

Evidence of prostate cancer screening in a UK region

1 reference

12 December 2020

Integrating research, practice, and policy: what we see depends on where we stand

1 reference

12 December 2020

Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.

1 reference

12 December 2020

A study of PSA requests from general practitioners received by one Dublin hospital.

1 reference

12 December 2020

A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA

1 reference

12 December 2020

Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement

1 reference

12 December 2020

Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation

1 reference

12 December 2020

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer

1 reference

12 December 2020

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

1 reference

12 December 2020

The stability of free and bound prostate-specific antigen.

1 reference

12 December 2020

Estimates of the cancer incidence and mortality in Europe in 2006.

1 reference

12 December 2020

Questionnaire order significantly increased response to a postal survey sent to primary care physicians

1 reference

12 December 2020

Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen

1 reference

12 December 2020

Three-year results of the Finnish prostate cancer screening trial.

1 reference

12 December 2020

10.1007/S11845-008-0216-1

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017